High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients

Table 3

Multivariate association of radiological response and survival outcomes with serum miR-122 concentration.

	Outcomes (n)	Total (n)	Univariate HR (95%CI)^a	Multivariate HR (95%CI)^a,b
12-week overall response
miR122_L group	5	294	Reference	Reference
miR122_H group	16	294	3.21 (1.19∼8.63)	3.22 (1.19∼8.64)
12-week disease control
miR122_L group	57	294	Reference	Reference
miR122_H group	83	294	1.47 (1.08∼1.97)	1.48 (1.08∼1.98)
12-week PFS
miR122_L group	57	294	Reference	Reference
miR122_H group	83	294	1.47 (1.08∼1.97)	1.48 (1.08∼1.98)
12-week OS
miR122_L group	255	294	Reference	Reference
miR122_H group	283	294	1.12 (1.07∼1.17)	1.12 (1.07∼1.18)
24-week overall response
miR122_L group	1	294	Reference	Reference
miR122_H group	8	294	8.01 (1.01∼63.57)	8.02 (1.01∼63.58)
24-week disease control
miR122_L group	11	294	Reference	Reference
miR122_H group	27	294	2.46 (1.24∼4.87)	2.47 (1.24∼4.88)
24-week PFS
miR122_L group	11	294	Reference	Reference
miR122_H group	27	294	2.46 (1.24∼4.87)	2.47 (1.24∼4.88)
24-week OS
miR122_L group	203	294	Reference	Reference
miR122_H group	241	294	1.19 (1.09∼1.31)	1.20 (1.09∼1.32)

^aPFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval. ^bThe multivariate COX model was adjusted by gender, age, annual income, HBeAg, HBV-DNA, serum albumin, serum total bilirubin, serum fetoprotein, ECOG score, maximum diameter of tumor, number of tumors, extent of tumor, portal vein invasion, and hepatic vein invasion.